Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 6/20 | 0.58 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.42 |
| ▸ | SELE | P16581 | 1/20 | 0.42 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.37 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.37 |
| ▸ | IDH1 | O75874 | 1/20 | 0.36 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.36 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.35 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.35 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2434748 | 0.85 | CYP2A6 (0.58) | CYP2A6ICAM1SELEMAPTCYP1A2 | |
| SCHEMBL6958993 | 0.82 | CYP2A6 (0.50) | CYP2A6ICAM1SELETRPM8MAPT | |
| SCHEMBL28221396 | 0.81 | CYP2A6 (0.46) | CYP2A6TRPM8MAPTCYP1A2ADRB2 | |
| SCHEMBL3463194 | 0.81 | CYP2A6 (0.49) | CYP2A6TRPM8MAPTCYP1A2ADRB2 | |
| SCHEMBL27759975 | 0.81 | CYP2A6 (0.58) | CYP2A6TRPM8MAPTCYP1A2ADRB2 | |
| SCHEMBL12489953 | 0.79 | CYP2A6 (0.47) | CYP2A6TRPM8MAPTCYP1A2HSD17B10 | |
| SCHEMBL9374785 | 0.78 | CYP2A6 (0.60) | CYP2A6MAPTCYP1A2PTPN2ASIC3 | |
| SCHEMBL13329682 | 0.78 | CYP2A6 (0.46) | CYP2A6TRPM8MAPTCYP1A2ADRB2 | |
| SCHEMBL16398343 | 0.78 | CYP2A6 (0.55) | CYP2A6ICAM1SELEHSD17B10PTPN2 | |
| SCHEMBL24601455 | 0.77 | CYP2A6 (0.58) | CYP2A6MAPTHSD17B10PTPN2ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4691558-A2 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | University Court of The University of Dundee (GB) | 2026-02-11 | — | — | EP | disclosed |
| US-20250295789-A1 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) | 2025-09-25 | — | — | US | disclosed |
| EP-2857018-B1 | Treatment or prophylaxis of proliferative conditions | UNIV COURT OF THE UNIV OF DUNDEE (GB) | 2025-09-03 | — | — | EP | disclosed |
| US-20220031852-A1 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) | 2022-02-03 | — | — | US | disclosed |
| US-20220031852-A1 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) | 2022-02-03 | — | — | US | disclosed |
| US-20200360521-A1 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) | 2020-11-19 | — | — | US | disclosed |
| US-20200360521-A1 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) | 2020-11-19 | — | — | US | disclosed |
| US-20200172530-A1 | Small Molecule Sensitization of BAX Activation for Induction of Cell Death | DANA-FARBER CANCER INSTITUTE, INC. | 2020-06-04 | — | — | US | disclosed |
| US-9919060-B2 | Treatment or prophylaxis of proliferative conditions | UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) | 2018-03-20 | — | — | US | disclosed |
| US-9919060-B2 | Treatment or prophylaxis of proliferative conditions | UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) | 2018-03-20 | — | — | US | disclosed |
| EP-2194045-A1 | SUBSTITUTED PYRAZOLE DERIVATIVE | Takeda Pharmaceutical Company Limited (JP) | 2010-06-09 | — | — | EP | disclosed |
| US-20100113780-A1 | HETEROMONOCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2010-05-06 | — | — | US | disclosed |
| US-20100105709-A1 | HETEROMONOCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2010-04-29 | — | — | US | disclosed |
| US-20100056526-A1 | HETEROMONOCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2010-03-04 | — | — | US | disclosed |
| WO-2009133970-A1 | CRYSTALLINE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-05 | — | — | WO | disclosed |
| US-20090270359-A1 | SUBSTITUTED PYRAZOLE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-29 | — | — | US | disclosed |
| US-20090176812-A1 | HETEROMONOCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2009-07-09 | — | — | US | disclosed |
| EP-2074117-A2 | HETEROMONOCYCLIC COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2009-07-01 | — | — | EP | disclosed |
| US-20080207654-A1 | HETEROMONOCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2008-08-28 | — | — | US | disclosed |
| WO-2008062905-A2 | HETEROMONOCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113780-A1 | HETEROMONOCYCLIC COMPOUND AND USE THEREOF | C1R, C1S, C3AR1 | CYP2A6 182/4885ICAM1 4395/4885SELE 3838/4885 |
| US-20200172530-A1 | Small Molecule Sensitization of BAX Activation for Induction of Cell Death | BAX, BAD, TMBIM6 | CYP2A6 3706/4885ICAM1 1761/4885SELE 3560/4885 |
| US-20200360521-A1 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | CYP1B1, UGT1A1, CYP1A1 | CYP2A6 62/4885ICAM1 1594/4885SELE 2949/4885 |
| US-20100056526-A1 | HETEROMONOCYCLIC COMPOUND AND USE THEREOF | CYP11B2, CYP11B1, NR3C2 | CYP2A6 83/4885ICAM1 3909/4885SELE 2078/4885 |
| US-20080207654-A1 | HETEROMONOCYCLIC COMPOUND AND USE THEREOF | C1R, C3AR1, C1S | CYP2A6 207/4885ICAM1 4216/4885SELE 3389/4885 |
| US-20090176812-A1 | HETEROMONOCYCLIC COMPOUND AND USE THEREOF | C1R, C1S, C3AR1 | CYP2A6 182/4885ICAM1 4395/4885SELE 3838/4885 |
| US-20220031852-A1 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | CYP1B1, UGT1A1, CYP1A1 | CYP2A6 62/4885ICAM1 1594/4885SELE 2949/4885 |
| US-20090270359-A1 | SUBSTITUTED PYRAZOLE DERIVATIVES | AR, NR5A1, NR3C2 | CYP2A6 512/4885ICAM1 4291/4885SELE 3538/4885 |
| US-20100105709-A1 | HETEROMONOCYCLIC COMPOUND AND USE THEREOF | C1R, C1S, C3AR1 | CYP2A6 182/4885ICAM1 4395/4885SELE 3838/4885 |
| US-20250295789-A1 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | CYP1B1, BRCA1, UGT1A1 | CYP2A6 81/4885ICAM1 1825/4885SELE 2882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.